Page last updated: 2024-10-27

gliclazide and Fasting Hypoglycemia

gliclazide has been researched along with Fasting Hypoglycemia in 47 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.

Research Excerpts

ExcerptRelevanceReference
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia."8.91Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015)
"Initiation of iGlarLixi resulted in similar TIR, A1C, FPG, weight and hypoglycemia compared with the more affordable option of starting iGlar + gliclazide in adults of South Asian origin with T2D."5.51Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. ( Aronson, R; Bajaj, HS; Bansal, N; Bhela, JS; Brown, RE; Chu, L; Dhillon, G; Gupta, R; Khandwala, H; Padda, JK; Venn, K, 2022)
"Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide."5.19A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. ( Abdallah, K; Hassanein, M; Schweizer, A, 2014)
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia."4.91Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015)
"Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk."4.91Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. ( Chan, SP; Colagiuri, S, 2015)
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs."4.90Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014)
"The risk for hypoglycemia when taking glyburide compared with modified-release gliclazide remains to be established in older adults in routine care."3.81The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. ( Clemens, KK; Dixon, SN; Fleet, JL; Garg, AX; Hramiak, I; McArthur, E, 2015)
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes."2.75Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."2.73Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
"Treatment with nateglinide plus metformin for up to 12 months was not associated with weight gain."2.73Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. ( Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P, 2007)
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."1.43Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016)
"Gliclazide or metformin-treated patients demonstrated lesser mortality risk than glibenclamide-treated ones in all four evaluation models, but age and duration stratification can influence this phenomenon in case of "first prescription model"."1.40Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients. ( Khalangot, M; Kovtun, V, 2014)
"A 74-year-old woman with type 2 diabetes mellitus who had been treated with a sulfonylurea for 6 years began experiencing frequent episodes of hypoglycemia."1.34Insulinoma causing hypoglycemia in a patient with type 2 diabetes. ( Chang, WH; Chen, TL; Lei, WY; Wang, CY; Wang, TE; Yang, TL, 2007)

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19903 (6.38)18.7374
1990's7 (14.89)18.2507
2000's15 (31.91)29.6817
2010's19 (40.43)24.3611
2020's3 (6.38)2.80

Authors

AuthorsStudies
Bajaj, HS1
Chu, L1
Bansal, N1
Brown, RE1
Dhillon, G1
Gupta, R1
Bhela, JS1
Padda, JK1
Khandwala, H1
Venn, K1
Aronson, R1
Kelty, E1
Tran, DD1
Atkinson, A1
Preen, DB1
Havard, A1
Mifsud, S1
Schembri, EL1
Fava, S1
Saberi, M1
Ramazani, Z1
Rashidi, H1
Saberi, A1
Raslan, IA1
McDonald, EG1
Lee, TC1
Gopal-Kothandapani, JS1
Wright, KP1
Sithambaram, S1
Natarajan, A1
Douros, A1
Yin, H1
Yu, OHY1
Filion, KB1
Azoulay, L1
Suissa, S1
Landman, GW2
de Bock, GH1
van Hateren, KJ2
van Dijk, PR1
Groenier, KH2
Gans, RO1
Houweling, ST1
Bilo, HJ1
Kleefstra, N2
Winkler, G1
Hassanein, M2
Abdallah, K1
Schweizer, A1
Zhao, F1
Ma, YF1
Wen, JX1
DU, YF1
Li, CL1
Li, GW1
Khalangot, M1
Kovtun, V1
Clemens, KK1
McArthur, E1
Dixon, SN1
Fleet, JL1
Hramiak, I1
Garg, AX1
Mbanya, JC1
Al-Sifri, S1
Abdel-Rahim, A1
Satman, I1
Chan, SP1
Colagiuri, S1
Oei, E1
Samad, N1
Visser, A1
Chowdhury, TA2
Fan, SL1
Wong, MG1
Perkovic, V1
Chalmers, J5
Woodward, M5
Li, Q2
Cooper, ME1
Hamet, P3
Harrap, S3
Heller, S4
MacMahon, S4
Mancia, G4
Marre, M4
Matthews, D1
Neal, B4
Poulter, N4
Rodgers, A2
Williams, B2
Zoungas, S4
van der Leeuw, J1
Visseren, FL1
van der Graaf, Y1
Grobbee, DE3
van Dijk, P1
Bouma, A1
Bilo, H1
Patel, A3
Billot, L2
Cooper, M2
Glasziou, P1
Grobbee, D1
Liu, L1
Mogensen, CE1
Pan, C1
Bompoint, S1
de Galan, BE3
Joshi, R1
Travert, F2
Walker, J1
White, R1
Vale, A1
Elliott, S2
Wass, J1
Reynolds, J1
Devendra, D1
Gohel, B1
Bravis, V1
Hui, E1
Salih, S1
Mehar, S1
Anderson, C1
Dufouil, C1
Pillai, A1
Hackett, M1
Heller, SR1
Lisheng, L1
Pan, CY1
Ling, GR1
Singh, K1
Wong, SY1
Toh, VK1
Ninomiya, T1
Kengne, AP1
Gupta, PS1
Green, AN1
Ragia, G1
Tavridou, A1
Petridis, I1
Manolopoulos, VG1
Langford, NJ1
Krentz, AJ1
Martin, U1
Ferner, RE1
Crawford, BA1
Perera, C1
Schernthaner, G1
Grimaldi, A1
Di Mario, U1
Drzewoski, J1
Kempler, P1
Kvapil, M1
Novials, A1
Rottiers, R1
Rutten, GE1
Shaw, KM1
Satyanarayana, S1
Sekhar, JR1
Kumar, KE1
Shannika, LB1
Rajanna, B1
Rajanna, S1
Chan, HY1
Tiu, SC1
Chan, OK1
Lei, WY1
Wang, TE1
Chen, TL1
Chang, WH1
Yang, TL1
Wang, CY1
Ristic, S1
Collober-Maugeais, C1
Cressier, F1
Tang, P1
Pecher, E1
Sener, A1
Akkan, AG1
Malaisse, WJ1
Tessier, D1
Dawson, K1
Tétrault, JP1
Bravo, G1
Meneilly, GS1
Braatvedt, GD1
van Staa, T1
Abenhaim, L1
Monette, J1
Paroni, R1
Comuzzi, B1
Arcelloni, C1
Brocco, S1
de Kreutzenberg, S1
Tiengo, A2
Ciucci, A1
Beck-Peccoz, P1
Genovese, S1
da Tos, V1
Maran, A1
Vigili de Kreutzenberg, S1
Marchetto, S1
Tadiotto, F1
Bettio, M1
Marescotti, MC1
Del Prato, S1
Abad, S1
Moachon, L1
Blanche, P1
Bavoux, F1
Sicard, D1
Salmon-Céron, D1
De Vigan, C1
Delporte, MP1
Thomas, M1
Perrault, M1
Grandmottet, P1
Narboni, G1
Schwager, JC1
Betchel, P1
Sandoz, M1
Vandel, B1
de Lavenne, P1
Peijnenburg, MA1
Shenfield, GM1
Boutagy, JS1
Webb, C1
Archambeaud-Mouveroux, F1
Nouaille, Y1
Nadalon, S1
Treves, R1
Merle, L1

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790]Phase 4119 participants (Actual)Interventional2018-10-02Completed
A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan[NCT01758380]Phase 4557 participants (Actual)Interventional2013-01-31Completed
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]8,494 participants (Actual)Observational2010-01-31Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]200 participants (Anticipated)Observational2012-01-31Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]160 participants (Actual)Interventional2013-12-31Active, not recruiting
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]Phase 4135 participants (Actual)Interventional2016-10-31Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]Phase 3104 participants (Anticipated)Interventional2016-12-31Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]465 participants (Actual)Interventional2015-08-31Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]150 participants (Anticipated)Interventional2016-11-30Active, not recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]Phase 4102 participants (Actual)Interventional2012-08-31Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]Phase 220 participants (Actual)Interventional2014-04-30Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]0 participants (Actual)Interventional2011-09-30Withdrawn
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213]Phase 460 participants (Actual)Interventional2012-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

Interventionpercentage (Mean)
Insulin Glargine, Metformin, Exenatide-2.43
Insulin Glargine, Metformin, Prandial Insulin0.44

HbA1C Levels

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Intervention% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide7.1
Insulin Glargine, Metformin, Prandial Insulin7.2

Number of Participants With Hypoglycemia

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

InterventionParticipants (Count of Participants)
Insulin Glargine, Metformin, Exenatide0
Insulin Glargine, Metformin, Prandial Insulin0

Weight Change During Trial

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

Interventionkg (Mean)
Insulin Glargine, Metformin, Exenatide-4.8
Insulin Glargine, Metformin, Prandial Insulin0.7

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

Interventionµg/ml (Median)
Sitagliptin0
Gliclazide8.4

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

Interventionmmol/L (Median)
Sitagliptin-0.2
Gliclazide-0.1

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

InterventionmmHg (Median)
Sitagliptin4
Gliclazide-9

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

Interventionmmol/L (Median)
Sitagliptin0.1
Gliclazide-0.1

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

Interventionscore on a scale (Median)
Sitagliptin3
Gliclazide1.8

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

Interventionscore on a scale (Median)
Sitagliptin9.5
Gliclazide9.4

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

Interventionkg (Median)
Sitagliptin-0.5
Gliclazide-0.6

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

InterventiondCt (Median)
Gliclazide-1.12
Sitagliptin0

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

InterventiondCt (Median)
Sitagliptin3.41
Gliclazide2.09

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin-0.07
Gliclazide0.43

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

Interventionpg/ml (Median)
Sitagliptin0
Gliclazide0

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

InterventionParticipants (Count of Participants)
Sitagliptin6
Gliclazide10

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

,
Interventionscore on a scale (Median)
DLQIHAQ-8HADS AnxietyHADS DepressionEQ-5D
Gliclazide-1.00.000-0.2
Sitagliptin0.00.0-100

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

,
InterventionParticipants (Count of Participants)
PASI 50PASI 75PASI 90
Gliclazide100
Sitagliptin100

Reviews

5 reviews available for gliclazide and Fasting Hypoglycemia

ArticleYear
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2

2014
[The use of gliclazide in individualized sulfonylurea therapy].
    Orvosi hetilap, 2014, Apr-06, Volume: 155, Issue:14

    Topics: Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Sulfonylurea Compoun

2014
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Diabetes research and clinical practice, 2015, Volume: 109, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gliclazide; H

2015
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Diabetes research and clinical practice, 2015, Volume: 110, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glicl

2015
[Hypoglycemia].
    Praxis, 2011, Oct-19, Volume: 100, Issue:21

    Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans;

2011

Trials

10 trials available for gliclazide and Fasting Hypoglycemia

ArticleYear
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
    Canadian journal of diabetes, 2022, Volume: 46, Issue:5

    Topics: Adult; Aged; Biosimilar Pharmaceuticals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations

2022
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Vascular health and risk management, 2014, Volume: 10

    Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dip

2014
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
    Diabetes care, 2016, Volume: 39, Issue:5

    Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin

2016
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    Journal of diabetes science and technology, 2017, Volume: 11, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Eld

2017
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab

2008
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
Severe hypoglycemia and risks of vascular events and death.
    The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla

2010
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
    European journal of clinical investigation, 2004, Volume: 34, Issue:8

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hyp

2004
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:4

    Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Femal

2007
Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
    Diabetic medicine : a journal of the British Diabetic Association, 1994, Volume: 11, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Humans; Hypoglycemia;

1994
Mechanisms of acute and chronic hypoglycemic action of gliclazide.
    Acta diabetologica, 2000, Volume: 37, Issue:4

    Topics: Acute Disease; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Gliclazide; Glu

2000

Other Studies

32 other studies available for gliclazide and Fasting Hypoglycemia

ArticleYear
Maternal and Neonatal Health Outcomes Associated with the Use of Gliclazide and Metformin for the Treatment of Diabetes in Pregnancy: A Record Linkage Study.
    Diabetes technology & therapeutics, 2020, Volume: 22, Issue:2

    Topics: Abnormalities, Drug-Induced; Adult; Diabetes, Gestational; Female; Gliclazide; Hospitalization; Huma

2020
A case of severe relapsing sulphonylurea-induced hypoglycaemia.
    BMJ case reports, 2019, Dec-02, Volume: 12, Issue:12

    Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemia; Middle Aged; Renal Insufficienc

2019
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
    Vascular health and risk management, 2020, Volume: 16

    Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie

2020
Missed Opportunities for Deprescription: A Teachable Moment.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Aged, 80 and over; Deprescriptions; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combina

2017
Dilemma of diagnosing sulphonylurea overdose in children: deliberations and considerations before reaching a diagnosis.
    BMJ case reports, 2017, Aug-28, Volume: 2017

    Topics: Adolescent; Blood Glucose; Diagnosis, Differential; Drug Overdose; Emergency Service, Hospital; Fema

2017
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Diabetes care, 2017, Volume: 40, Issue:11

    Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus

2017
Parsimonious model for blood glucose level monitoring in type 2 diabetes patients.
    Biomedical and environmental sciences : BES, 2014, Volume: 27, Issue:7

    Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide;

2014
Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
    Current diabetes reviews, 2014, Volume: 10, Issue:5

    Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Metform

2014
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
    Canadian journal of diabetes, 2015, Volume: 39, Issue:4

    Topics: Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fem

2015
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
    Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:9

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2;

2016
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
    Diabetologia, 2016, Volume: 59, Issue:12

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations

2016
Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge.
    British journal of clinical pharmacology, 2009, Volume: 67, Issue:2

    Topics: Aged; Cholecystectomy; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypertension; Hypoglycemia; Ma

2009
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
    International journal of clinical practice, 2009, Volume: 63, Issue:10

    Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fastin

2009
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
    Diabetologia, 2009, Volume: 52, Issue:11

    Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A

2009
Severe neuroglycopaenia secondary to severe hypoglycaemia from serendipitous overdose of gliclazide without adrenergic or autonomic response.
    Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:11

    Topics: Blood Glucose; Drug Overdose; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Male

2009
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
    Diabetes research and clinical practice, 2012, Volume: 98, Issue:1

    Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Typ

2012
Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge.
    Postgraduate medical journal, 2003, Volume: 79, Issue:928

    Topics: Female; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Recurrence

2003
Octreotide treatment for sulfonylurea-induced hypoglycaemia.
    The Medical journal of Australia, 2004, May-17, Volume: 180, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypogly

2004
Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats.
    Molecular and cellular biochemistry, 2006, Volume: 283, Issue:1-2

    Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Th

2006
Dual aetiologies for hyperinsulinaemic hypoglycaemia in one patient.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2007, Volume: 13, Issue:1

    Topics: Adult; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglycemic Agents; Insulinoma; Male; Pan

2007
Insulinoma causing hypoglycemia in a patient with type 2 diabetes.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2007, Volume: 106, Issue:5

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglyc

2007
Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.
    Acta diabetologica, 1995, Volume: 32, Issue:1

    Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Forensic Medicine;

1995
Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
    The New Zealand medical journal, 1997, May-23, Volume: 110, Issue:1044

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Hormones; Humans; Hypoglycemia; Hypogl

1997
Rates of hypoglycemia in users of sulfonylureas.
    Journal of clinical epidemiology, 1997, Volume: 50, Issue:6

    Topics: Adult; Aged; Chlorpropamide; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemia; Hypogly

1997
Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent.
    Prescrire international, 1998, Volume: 7, Issue:36

    Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evalua

1998
Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
    Clinical chemistry, 2000, Volume: 46, Issue:11

    Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdose; Electrophores

2000
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.
    British journal of clinical pharmacology, 2001, Volume: 52, Issue:4

    Topics: Anti-Infective Agents; Antifungal Agents; Diabetes Complications; Diabetes Mellitus; Drug Interactio

2001
[Hypoglycemic complications of oral drug therapy of diabetes mellitus. 21 cases].
    La Nouvelle presse medicale, 1976, Apr-03, Volume: 5, Issue:14

    Topics: Age Factors; Aged; Diabetes Mellitus; Diabetic Coma; Drug Interactions; Female; Gliclazide; Glyburid

1976
[3 cases of hypoglycemia during treatment with gliclazide (1): contribution of phaarmocokinetics to the development of pathogenetic hypotheses].
    Annales de medecine interne, 1977, Volume: 128, Issue:10

    Topics: Adult; Aged; Female; Gliclazide; Humans; Hypoglycemia; Male; Sulfonylurea Compounds

1977
[Sulfonylurea preparations and hypoglycemia].
    Nederlands tijdschrift voor geneeskunde, 1992, Jan-25, Volume: 136, Issue:4

    Topics: Gliclazide; Humans; Hypoglycemia; Probability

1992
A screening test for detecting sulfonylureas in plasma.
    Therapeutic drug monitoring, 1990, Volume: 12, Issue:4

    Topics: Aged; Aged, 80 and over; Chlorpropamide; Chromatography, High Pressure Liquid; Female; Gliclazide; G

1990
Interaction between gliclazide and cimetidine.
    European journal of clinical pharmacology, 1987, Volume: 31, Issue:5

    Topics: Aged; Cimetidine; Drug Interactions; Gliclazide; Humans; Hypoglycemia; Male; Sulfonylurea Compounds

1987